Last reviewed · How we verify
Punctate keratitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Lotemax · Bausch Health
- Tobi · Novartis
- Lotemax · Tufts Medical Center
- Decadron · Generic (originally Merck)
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Punctate keratitis patent landscape — cliff calendar, originator estates, attackable patents
- Punctate keratitis treatment landscape brief
- Punctate keratitis treatment updates RSS
Frequently asked questions about Punctate keratitis
What drugs treat Punctate keratitis?
Tracked treatments include Ramycin, Lotemax, Tobi, Decadron, Vantobra, Nebcin.
What is the treatment for Punctate keratitis?
Standard treatment for Punctate keratitis includes Ramycin, Lotemax, Tobi, Decadron, Vantobra. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Punctate keratitis patent cliff · Punctate keratitis CI report
- Treatment: Ramycin
- Treatment: Lotemax · Bausch Health
- Treatment: Tobi · Novartis
- Treatment: Lotemax · Tufts Medical Center
- Treatment: Decadron · Generic (originally Merck)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing